Innoviz Technologies grants options and RSUs

Innoviz Technologies Ltd. reported equity awards to Chief R&D Officer Avishay Ben Moscovici on August 4, 2026.

Rhea-AI Filing Summary

Innoviz Technologies Ltd. reported equity awards to Chief R&D Officer Avishay Ben Moscovici on August 4, 2026. He received 71,072 share options for ordinary shares with a 0.4200 per share exercise price, expiring on 2033-08-04, and 66,336 Restricted Share Units (RSUs). Both the options and RSUs vest one-fourth on August 4, 2027, with the remainder vesting quarterly through 2030, subject to his continued service. After these grants, he reported 397,001 ordinary shares, including 213,724 shares issuable upon RSU vesting, and 71,072 share options.

Insider Trade Summary

Grant/Award: 137,408 shares

Grant/Award 2 txns

Insider Moscovici Avishay Ben

Role Chief R&D Officer

Type	Security	Shares	Price	Value
Grant/Award	Share Option F4	71,072	$0.00	$0.00
Grant/Award	Ordinary Shares F1, F2, F3	66,336	$0.00	$0.00

Holdings After Transaction: Share Option — 71,072 contracts (Direct); Ordinary Shares — 397,001 shares (Direct)

Footnotes (4)

1. F1. Represents 66,336 Restricted Share Units (RSUs) granted on August 4, 2026, one-fourth vesting on August 4, 2027, remainder vesting quarterly through 2030, subject to the Reporting Person remaining a service provider of the Issuer on the vesting date. Each RSU represents a contingent right to receive one ordinary share. No exercise price is applicable.
2. F2. Includes 213,724 ordinary shares issuable upon vesting of RSUs; of which (a) 2,005 RSUs granted August 9, 2022, vesting quarterly through 2026; (b) 8,540 RSUs granted August 1, 2023, vesting quarterly through 2027; (c) 12,471 RSUs granted February 27, 2024, with 2,013 vesting quarterly through 2027 and 10,458 vesting quarterly through 2028; (d) 25,452 RSUs granted August 20, 2024, vesting quarterly through 2028; (e) 13,684 RSUs granted February 25, 2025, vesting quarterly through 2029; (f) 37,188 RSUs granted August 5, 2025, vesting quarterly through 2029; (g) 48,048 RSUs granted November 11, 2025, one-fourth vesting on November 11, 2026, remainder vesting quarterly through 2029; and (h) 66,336 RSUs granted August 4, 2026, one-fourth vesting on August 4, 2027, remainder vesting quarterly through 2030.
3. F3. Vesting is subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date. Each RSU represents a contingent right to receive one ordinary share.
4. F4. Share options granted on August 4, 2026, one-fourth vesting on August 4, 2027, remainder vesting quarterly through 2030, subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date.

Key Figures

Share options granted: 71,072 share options Option exercise price: 0.4200 per share RSUs granted: 66,336 RSUs +3 more

6 metrics

Share options granted 71,072 share options Granted on August 4, 2026 to the Chief R&D Officer

Option exercise price 0.4200 per share Exercise price for 71,072 share options expiring on 2033-08-04

RSUs granted 66,336 RSUs Restricted Share Units granted August 4, 2026, vesting through 2030

Ordinary shares after grants 397,001 ordinary shares Total ordinary shares reported as owned after August 4, 2026 transactions

Shares issuable from RSUs 213,724 ordinary shares Ordinary shares issuable upon vesting of outstanding RSUs

Option expiration date 2033-08-04 Expiration date for the 71,072 share options granted

Key Terms

Restricted Share Units (RSUs), exercise price, vesting, ordinary shares, +1 more

5 terms

Restricted Share Units (RSUs) financial

"Represents 66,336 Restricted Share Units (RSUs) granted on August 4, 2026"

Restricted share units (RSUs) are a form of employee pay where a company promises to give shares (or their cash value) to workers after certain conditions, usually time or performance, are met. For investors, RSUs matter because they can increase the number of shares outstanding and signal how management is being paid and incentivized—think of them as delayed bonuses that convert into ownership when vesting conditions are satisfied.

exercise price financial

"No exercise price is applicable"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"one-fourth vesting on August 4, 2027, remainder vesting quarterly through 2030"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

ordinary shares financial

"Each RSU represents a contingent right to receive one ordinary share"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

service provider financial

"subject to the Reporting Person remaining a service provider of the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity awards did Innoviz Technologies (INVZ) report for August 4, 2026?

Innoviz Technologies reported new equity awards to Chief R&D Officer Avishay Ben Moscovici on August 4, 2026. He received 71,072 share options and 66,336 Restricted Share Units (RSUs), both vesting over several years, subject to his continued service with the company.

How many options and RSUs were granted to the Innoviz (INVZ) Chief R&D Officer?

The Chief R&D Officer was granted 71,072 share options and 66,336 RSUs. The options carry a 0.4200 per share exercise price, while each RSU represents a contingent right to receive one ordinary share with no exercise price applicable.

What is the vesting schedule for the new Innoviz (INVZ) RSU and option grants?

Both the 66,336 RSUs and 71,072 share options vest one-fourth on August 4, 2027. The remaining three-fourths vest quarterly through 2030, conditioned on the reporting person remaining a service provider on each applicable vesting date.

What are Avishay Ben Moscovici’s reported Innoviz (INVZ) share holdings after these grants?

After the August 4, 2026 grants, Avishay Ben Moscovici reported 397,001 ordinary shares. This figure includes 213,724 ordinary shares issuable upon vesting of RSUs, in addition to holding 71,072 share options for ordinary shares.

What is the exercise price and expiration for the new Innoviz (INVZ) share options?

The newly granted 71,072 share options have a 0.4200 per share exercise price and expire on 2033-08-04. Vesting begins with one-fourth on August 4, 2027, with the remaining options vesting quarterly through 2030, subject to continued service conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 04:13 PM Accepted by SEC EDGAR 08/05/2026 - 04:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moscovici Avishay Ben

(Last) (First) (Middle)

C/O INNOVIZ TECHNOLOGIES LTD.

5 URI ARIAV STREET, BUILDING C

(Street)

ROSH HA'AIN 4809202

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Innoviz Technologies Ltd. [ INVZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief R&D Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/04/2026		A		66,336(1)	A	$0.00	397,001(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$0.42	08/04/2026		A		71,072		(4)	08/04/2033	Ordinary Shares	71,072	$0.00	71,072	D

Explanation of Responses:

1. Represents 66,336 Restricted Share Units (RSUs) granted on August 4, 2026, one-fourth vesting on August 4, 2027, remainder vesting quarterly through 2030, subject to the Reporting Person remaining a service provider of the Issuer on the vesting date. Each RSU represents a contingent right to receive one ordinary share. No exercise price is applicable.

2. Includes 213,724 ordinary shares issuable upon vesting of RSUs; of which (a) 2,005 RSUs granted August 9, 2022, vesting quarterly through 2026; (b) 8,540 RSUs granted August 1, 2023, vesting quarterly through 2027; (c) 12,471 RSUs granted February 27, 2024, with 2,013 vesting quarterly through 2027 and 10,458 vesting quarterly through 2028; (d) 25,452 RSUs granted August 20, 2024, vesting quarterly through 2028; (e) 13,684 RSUs granted February 25, 2025, vesting quarterly through 2029; (f) 37,188 RSUs granted August 5, 2025, vesting quarterly through 2029; (g) 48,048 RSUs granted November 11, 2025, one-fourth vesting on November 11, 2026, remainder vesting quarterly through 2029; and (h) 66,336 RSUs granted August 4, 2026, one-fourth vesting on August 4, 2027, remainder vesting quarterly through 2030.

3. Vesting is subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date. Each RSU represents a contingent right to receive one ordinary share.

4. Share options granted on August 4, 2026, one-fourth vesting on August 4, 2027, remainder vesting quarterly through 2030, subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date.

	/s/ Dafna Raz - Attorney-in-Fact	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)